KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity

被引:44
作者
Poirel, Laurent [1 ,2 ,3 ,4 ,5 ]
Vuillemin, Xavier [1 ,2 ]
Juhas, Mario [1 ,2 ]
Masseron, Amandine [1 ,2 ]
Bechtel-Grosch, Ursina [6 ]
Tiziani, Simon [7 ]
Mancini, Stefano [8 ]
Nordmann, Patrice [1 ,2 ,3 ,4 ,5 ,9 ,10 ]
机构
[1] Univ Fribourg, Fac Sci & Med, Emerging Antibiot Resistance Unit, Fribourg, Switzerland
[2] Univ Fribourg, Fac Sci & Med, Med & Mol Microbiol, Fribourg, Switzerland
[3] Univ Fribourg, Swiss Natl Reference Ctr Emerging Antibiot Resist, Fribourg, Switzerland
[4] INSERM, European Unit, IAME, Paris, France
[5] Univ Fribourg, Fribourg, Switzerland
[6] Univ Hosp Zurich, Dept Trauma Surg, Zurich, Switzerland
[7] Univ Zurich, Univ Hosp Zurich, Inst Intens Med, Zurich, Switzerland
[8] Univ Zurich, Inst Med Microbiol, Zurich, Switzerland
[9] Univ Hosp Ctr, Inst Microbiol, Lausanne, Switzerland
[10] Univ Lausanne, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
KPC; ceftazidime-avibactam; Klebsiella pneumoniae; KLEBSIELLA-PNEUMONIAE; LACTAMASE;
D O I
10.1128/AAC.00321-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.
引用
收藏
页数:5
相关论文
共 23 条
[1]   Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient [J].
Athans, Vasilios ;
Neuner, Elizabeth A. ;
Hassouna, Habiba ;
Richter, Sandra S. ;
Keller, George ;
Castanheira, Mariana ;
Brizendine, Kyle D. ;
Mathers, Amy J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (01)
[2]   Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering [J].
Barnes, Melissa D. ;
Winkler, Marisa L. ;
Taracila, Magdalena A. ;
Page, Malcolm G. ;
Desarbre, Eric ;
Kreiswirth, Barry N. ;
Shields, Ryan K. ;
Minh-Hong Nguyen ;
Clancy, Cornelius ;
Spellberg, Brad ;
Papp-Wallace, Krisztina M. ;
Bonomo, Robert A. .
MBIO, 2017, 8 (05)
[3]   Identification of plasmids by PCR-based replicon typing [J].
Carattoli, A ;
Bertini, A ;
Villa, L ;
Falbo, V ;
Hopkins, KL ;
Threlfall, EJ .
JOURNAL OF MICROBIOLOGICAL METHODS, 2005, 63 (03) :219-228
[4]  
Compain F, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00451-17, 10.1128/aac.00451-17]
[5]   Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates [J].
Diancourt, L ;
Passet, V ;
Verhoef, J ;
Grimont, PAD ;
Brisse, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) :4178-4182
[6]  
EUCAST, 2020, BREAKP TABL INT MICS
[7]   Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam [J].
Galani, I. ;
Antoniadou, A. ;
Karaiskos, I. ;
Kontopoulou, K. ;
Giamarellou, H. ;
Souli, M. .
CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (06) :763.e5-763.e8
[8]   Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand [J].
Girlich, D ;
Naas, T ;
Leelaporn, A ;
Poirel, L ;
Fennewald, M ;
Nordmann, P .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :603-611
[9]   Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases [J].
Haidar, Ghady ;
Clancy, Cornelius J. ;
Shields, Ryan K. ;
Hao, Binghua ;
Cheng, Shaoji ;
Nguyen, M. Hong .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (05)
[10]   Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2 [J].
Hemarajata, Peera ;
Humphries, Romney M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) :1241-1243